Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

Cyclin-dependent kinase (CDK) inhibitors have the potential to induce cell-cycle arrest and apoptosis in cancer cells. Seliciclib (CYC202 or R-roscovitine) is a potent CDK inhibitor currently undergoing phase-2 clinical testing in lung and B-cell malignancies. Here we studied the in vitro cytotoxic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Raje, Noopur, Kumar, Shaji, Hideshima, Teru, Roccaro, Aldo, Ishitsuka, Kenji, Yasui, Hiroshi, Shiraishi, Norihiko, Chauhan, Dharminder, Munshi, Nikhil C., Green, Simon R., Anderson, Kenneth C.
Formato: Artigo
Lenguaje:Inglês
Publicado: © 2005 by The American Society of Hematology 2005
Materias:
Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895150/
https://ncbi.nlm.nih.gov/pubmed/15827128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-01-0320
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares